Awareness, concern, and communication between physicians and patients on bone health in cancer
- 231 Downloads
This study aims to explore physician–patient communications about bone metastases and cancer treatment-induced bone loss (CTIBL).
The study utilizes online survey of patients with breast cancer, prostate cancer, and multiple myeloma, and the physicians who treat them.
Even though 69 and 48 % of patients with nonmetastatic breast and prostate cancer aware of treatment-induced bone loss, only 39 and 23 %, respectively, were concerned about bone loss. Yet, 62 and 71 % of oncologists treating breast and prostate cancer felt that their patients were concerned. Among patients with metastatic breast and prostate cancer, two thirds had not discussed treatment for bone metastases with their doctor; when discussed, 88 and 91 % of discussions were initiated by the doctor, usually prior to initiating treatment. Most myeloma patients (77 %) had discussed treatment options with their physicians; 99 % of hematologists reported discussing treatment of bone disease with patients.
Physicians are primary sources of information to patients regarding bone health. There is a gap between what physicians assume their patients know about bone health and the patients’ perceptions, presenting a need for systematic awareness and education.
KeywordsCancer treatment-induced bone loss Bone metastases Skeletal-related event Prostate cancer Breast cancer Multiple myeloma
The survey was sponsored by Amgen. The authors thank Supriya Srinivasan, PhD, of Scientia Medical Communications, LLC, for assistance with writing and editing this manuscript.
Conflict of interest
BM was an employee of Amgen at the time the study was conducted and owns Amgen stock. JWM is on Amgen’s speaker bureau for the use of denosumab in prostate cancer. DT, BGMD, and KSF have no conflicts of interest to disclose.
- 5.Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090PubMedCrossRefGoogle Scholar
- 7.Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164Google Scholar
- 9.Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30Google Scholar
- 10.National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: multiple myeloma, version 1. 2012. www.nccn.org. Accessed 25 March 2012
- 12.National Comprehensive Cancer Network (2012) Clinical Practice guidelines in oncology: breast cancer, version 1. 2012. www.nccn.org. Accessed 25 March 2012
- 13.National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: prostate cancer, version 1. 2012. www.nccn.org. Accessed 25 March 2012
- 16.Gralow JR, Biermann JS, Farooki A et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7:S1–S32Google Scholar